Participated · Series B · Jul 2025

Blue Dot Touch (also reported as Link-Touch or Landian Touch) develops high-performance six-axis force sensors and joint force sensors. The company claims domestic market share exceeding 70% for six-axis force sensors and about 95% for joint force sensors, serving nearly every top-tier industry player. It reports sensor accuracy improved to 0.1%FS and response frequency up to 10 kHz through mastery of elastomer design, embedded hardware circuits, structural decoupling algorithms, and six-axis synchronous calibration. Blue Dot Touch also says it has reduced unit volume and weight by 80–90%. Its shareholder base includes strategic and financial investors such as Sequoia China, CATL's Puquan Capital, AgiBot, Yinhe General, SAIC's investment arm, and SMIIC industrial capital. The company has completed seven funding rounds to date.

Participated · Equity · Jul 2022

Yuexin Semiconductor (粤芯半导体) is a market-driven, Guangzhou-grown foundry that specializes in analog chip manufacturing and is the Greater Bay Area's only 12‑inch analog chipmaker in full mass production. The company operates a customized foundry model that has deep ties to the automotive chip supply chain and concentrates on differentiated high-end analog process technologies. Phase I and II projects are completed and in production, and the company reports a thousand‑person professional team, established technology reserves and an IP portfolio. Existing industry customers have validated its capabilities and the firm aims to raise China’s analog chip self-sufficiency by expanding capacity. Yuexin plans to use the latest financing to build a new project phase, further scale 12‑inch analog specialty processes, and focus on industrial‑ and automotive‑grade mid-to-high-end analog chips to support upstream and downstream ecosystem innovation.

Participated · Series C · Mar 2022

DataGrand is a Shanghai-based AI and RPA vendor whose platform combines Robotic Process Automation (RPA) with Intelligent Document Processing (IDP) to enable smart office automation. Its system supports scenarios such as contract review, data search and recommendation, automatic reporting and text analysis. Core technologies and solutions include natural language processing (NLP), optical character recognition (OCR), knowledge graphs, intelligent recommendations and hyperautomation. Founded in 2015, the company has deployed its offerings for many Fortune 500 companies’ smart office use cases. DataGrand completed a $90M Series C financing to bolster its market position. It intends to use the proceeds to strengthen its lead in Intelligent RPA and accelerate technical innovation and industrial application of its core products and solutions. DataGrand is a Chinese AI company founded in 2015 and led by CEO Dr. Chen Yunwen. It develops and applies natural language processing (NLP), optical character recognition (OCR), knowledge-graph and RPA technologies to deliver text automation solutions such as documentation review, intelligent recommendation, intelligent search and knowledge mapping. The company notes its solution does not use Microsoft’s underlying development frameworks and is deployed across dozens of vertical industries and by more than 100 enterprises. DataGrand has established strategic partnerships with Microsoft, Sogou and China Ping An Group. Customers include China UnionPay, Shenzhen Stock Exchange, HSBC, Deloitte, China Mobile, Huawei, Haier and Decathlon. It closed a CNY 270m (USD 38m) B+ funding round and intends to use the proceeds to scale up its business.

Participated · Series E · Feb 2022

Yunzhangfang is a corporate finance and tax management SaaS provider that develops and sells automatic tax reporting systems and other taxation products. Since its inception in 2015, the company has combined internet technology and artificial intelligence with taxation data to offer more intelligent and automatic taxing solutions. It focuses on helping bookkeeping and accounting agencies and claims service coverage across 36 tax regions. The firm offers integrated and automatic finance and taxation management tools intended to lower taxation cost and increase effectiveness. Yunzhangfang plans to invest proceeds from its recent fundraise into IT infrastructure, brand management, product R&D and other areas. The company announced a significant Series E financing in February 2022, signaling a strong capital position to pursue its product and technology roadmap. Yunzhangfang provides integrated, automatic bookkeeping tools that initially served bookkeeping agencies and later expanded to offer SMEs tools to evaluate and prevent corporate taxation risks and to assist with employees' personal income tax and public insurance premium payments. The platform automates manual bookkeeping work and aims to improve efficiency for professional agencies and SMEs. The company says it has served more than 3,000 bookkeeping agencies and over 1.4 million SMEs across 26 provincial regions in China. Founded in 2015 and based in Nanjing, Yunzhangfang has seen growing demand amid recent changes to China’s personal income tax rules that increased compliance complexity for companies. The business recently closed an $85 million Series D and previously raised an RMB 300 million (42.8 million) Series C led by Hillhouse Capital in November 2018. New funds will be used for technological research in robotic process automation, elastic computing, platform-as-a-service and financial knowledge graph, plus marketing to expand the client base and talent hiring.

Led · Series D · Mar 2021

CalciMedica is a clinical-stage biotechnology company focused on discovery and development of small-molecule CRAC channel inhibitors to treat severe acute and chronic inflammatory diseases. Its lead product, Auxora, has data from a Phase 2a acute pancreatitis trial and a Phase 2 COVID-19 pneumonia trial suggesting prevention of organ tissue damage and rapid restoration of organ function. Auxora is currently being evaluated in a blinded, placebo-controlled trial in severe and critical COVID-19 pneumonia (up to 400 patients planned; over 200 randomized to date) and a Phase 2b trial in acute pancreatitis is set to start enrolling in the coming weeks. The company plans to use proceeds from the Series D financing to advance clinical development across Auxora and its broader CRAC inhibitor portfolio. CalciMedica is privately held and headquartered in San Diego, California, and the announced financing will be completed in multiple private closings. The financing also included board augmentation with Zafi Avnur, Ph.D., of Quark Venture joining the board, indicating investor operational involvement. CalciMedica is a La Jolla, California-based clinical-stage biotechnology company focused on discovery and development of drugs that target calcium release-activated calcium (CRAC) channels for treatment of acute and chronic inflammatory diseases. The company is advancing Auxora (formerly CM4620-IE), a potent and selective small-molecule CRAC channel inhibitor that prevents CRAC channel overactivation. CRAC channels control the entry of calcium into immune and other cell types, and CalciMedica says modulating this pathway can reduce detrimental calcium signaling in inflammatory conditions. The company intends to use the new funding to advance ongoing clinical trials evaluating Auxora in patients with COVID-19 pneumonia requiring oxygen therapy and to accelerate commercial manufacturing for the drug. CalciMedica is led by CEO Rachel Leheny, Ph.D. In May 2020 the company raised $15M in a Series C financing led by Valence Life Sciences with participation from Bering Capital, Mesa Verde Venture Partners and existing investor Sanderling Ventures. CalciMedica is developing selective CRAC channel inhibitors intended to treat inflammatory and autoimmune diseases. Over the past year the company reported significant progress identifying and characterizing CRAC channel inhibitors with attractive pharmaceutical properties. Management states these candidates have the potential to become safe and effective drugs for inflammatory and autoimmune indications. Financially, CalciMedica closed the second tranche of a $12M Series C financing and has raised a total of $19M in equity funding to date. Prior financings include a seed round from SR One in December 2006 and a Series B in August 2007. The Series C round included participation from BiogenIdec New Ventures, Sanderling Ventures and SR One. CalciMedica is a San Diego-based biotechnology company focused on autoimmune and inflammatory disease. The reporting states the company raised $1.53 million in its first funding round. The funding was provided by S.R. One, according to a regulatory filing cited by PE Hub. The articles do not disclose specific product candidates, pipeline details, or operating metrics such as revenue or user numbers. No future plans or use of proceeds were detailed in the coverage. The public reporting is limited to the amount raised, the investor, and the regulatory filing citation.